Skip to content

Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. is focused on the use of cyclodextrins in drug development in treatment for Niemann-Pick disease Type C (NPC). The mission of Cyclo Therapeutics, Inc. is to develop, manufacture, and distribute cyclodextrin-based high value products. Their products treat disease, improve quality of life, and provide solutions in a broad range of applications including pharmaceutical formulation, medical diagnostics, cosmetics, nutraceuticals, and nutrition.

For more information, please visit cyclotherapeutics.com.

This page is dedicated to news and information about Cyclo Therapeutic’s therapies for use in Niemann-Pick disease Types C (NPC). Information is released as it becomes available.

Patient and Trial Information

Lise Kjems, Chief Medical Officer
lise.kjems@cyclodex.com

Lori Gorski, Patient Liaison
lori.gorski@cyclodex.com

Latest News

The following update has been shared with the NNPDF from Cyclo Therapeutics on their TransportNPC trial, which is currently enrolling. Read complete update.

10/12/2021

Cyclo Therapeutics announces their design of pivotal Phase 3 study evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1 patient enrollment is on track to commence in Q2 2021. For complete announcement click here.

04/27/2021

Cyclo Therapeutics announces their Phase III pivotal trial using Trappsol® Cyclo™ will be enrolling soon. For complete announcement click here.

04/14/2021

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1). For complete announcement click here.

03/25/2021

Cyclo Therapeutics receives positive opinion from the Paediatric Committee of the European Medicines Agency on the agreement of a paediatric investigation plan for Trappsol® Cyclo™. For complete announcement click here.

03/09/2021

Cyclo Therapeutics, Inc. announces it’s last patient last visit in their Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick disease Type C. For complete announcement click here.

03/04/2021

Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021. For complete announcement click here.

02/09/2021

Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021. For complete announcement click here.

01/26/2021

Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick disease Type C. For complete announcement click here.

01/05/2021

Cyclo Therapeutics announces Two Presentations at WORLDSymposium2021.

CLICK HERE For complete announcement.

11/19/2020

Cyclo Therapeutics announces its Phase 3 pivotal program can begin enrollment of Trappsol® Cyclo™ for treatment of Niemann-Pick disease Type C. 

CLICK HERE For complete announcement.

10/21/2020

Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

CLICK HERE for complete announcement.

09/21/2020

Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick disease Type C1 (NPC1)

CLICK HERE for complete announcement.

09/08/2020

Cyclo Therapeutics Closes $2.8 Million Private Placement led by Novit LP with $1.0 Million

CLICK HERE for complete announcement.

08/27/2020

A Message from Cyclo Therapeutics to the NPC Community

CLICK HERE for complete announcement.

07/17/2020

Cyclo Therapeutics’ Clinical Data Webinar Recording Available on Company Website

CLICK HERE for complete announcement.

05/28/2020

Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick disease Type C1 (NPC1)

CLICK HERE for complete announcement.

05/20/2020

Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT

CLICK HERE for complete announcement.

05/19/2020

Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick disease Type C1

CLICK HERE for complete announcement.

05/19/2020

Cyclo Therapeutics Inc. Announces $2.0 Million Private Placement Closing

CLICK HERE for complete announcement.

04/27/2020

Cyclo Therapeutics Inc. Announces Positive Safety Profile of its Drug Trappsol® Cyclo™ in the Treatment of Niemann-Pick disease Type C

CLICK HERE for complete announcement.

03/23/2020

Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick disease Type C1

CLICK HERE for complete announcement.

03/02/2020

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick disease Type C

Cyclo Therapeutics, Inc. today announced that it has completed patient enrollment in its Phase I/II trial to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ administered intravenously to Niemann-Pick disease Type C1 (NPC1) patients.

CLICK HERE FOR COMPLETE ANNOUNCEMENT

02/20/2020

Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C

Cyclo Therapeutics, Inc. today announced that the last patient has undergone the final assessment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to NPC patients.

CLICK HERE FOR COMPLETE ANNOUNCEMENT

02/12/2020

Cyclo Therapeutics, Inc. Poster Presentation of Clinical Trial Data on Niemann-Pick Type C Disease at the 16th Annual WORLDSymposium Now Available

CLICK HERE FOR COMPLETE ANNOUNCEMENT

02/05/2020

Cyclo Therapeutics to Present Clinical Trial Data on NPC at 2020 WORLDSymposium

CLICK HERE FOR COMPLETE ANNOUNCEMENT

12/18/2019 jjb

Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Pivotal Trial in Niemann-Pick disease Type C

CLICK HERE FOR COMPLETE ANNOUNCEMENT

11/8/2019 jjb

Cyclo Therapeutics Announces Its Publication of the Most Extensive Set of Case Study Reports To-date on Expanded Access Use of Hydroxypropyl Beta Cyclodextrin in Niemann-Pick disease Type C.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/31/2019 jjb

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick disease Type C.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/22/2019 jjb

Cyclo Therapeutics, Inc. Announces Maurizio Scarpa, MD as EU Coordinating Investigator for the Company’s Pivotal Trial in Niemann-Pick disease Type C.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/09/2019 jjb

CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick disease Type C.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

09/14/2019 jjb

CTD Announces New Data Presented at Annual Gathering of Patients and Families Tackling NPC.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

08/14/2019 jjb

CTD Holdings, Inc. Appoints Head of Global Affairs

CTD Holdings, Inc. is pleased to announce the appointment of Mr. Michael Lisjak as Global Head of Regulatory Affairs and Senior Vice President for Business Development.

CLICK HERE FOR COMPLETE ANNOUNCEMENT

07/08/2019 jjb

CTD Holdings, Inc. Announces Closing on $7.4 Million Private Placement.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

05/31/2019 jjb

CTD Holdings, Inc. Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol® Cyclo™ for NPC

CLICK HERE FOR COMPLETE ANNOUNCEMENT

05/23/2019 jjb

CTD Holdings, Inc. Shares Update on Ongoing Recruitment for Niemann-Pick Type C1 Study

CLICK HERE FOR UPDATE

04/10/2019 jjb

NNPDF Industry Update Webinar Series featuring CTD Holdings, Inc.

CLICK HERE FOR RECORDING

03/15/2019 jjb

Additional Travel Funding For Those Participating in PFDD Meeting

CTD Holdings is providing funding through NNPDF to support families with travel assistance to the upcoming NPC Externally-Led Patient-Focused Drug Development Meeting (PFDD). Support is intended for additional family members who would like to attend the meeting but are not eligible for subsidy otherwise. As the national patient organization, NNPDF is glad to assist in providing this support to the Niemann-Pick community.

Externally-led PFDD events are driven by people with NPC and their advocates to provide the FDA with personal perspectives and experiences from the community, including challenges faced on a daily basis in living with NPC and hopes for future treatments. It seeks to better emphasize the voice of the patient in the therapy development process so that these therapies are better tailored to the needs and preferences of patients.

For more information on how to apply for this financial assistance, please contact Laurie Turner, Family Services Manager at familyservices@nnpdf.org.

For more information on the PFDD, or to register for the event, visit niemannpickc-pfdd.com.

2/28/2019 jjb

CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick Disease Type C

CLICK HERE FOR COMPLETE ANNOUNCEMENT

2/7/2019 jjb

CTD Holdings Announces Partnership with United BioSource LLC to support the Extension Protocol for its Phase I Clinical Trial in the US

CLICK HERE FOR COMPLETE ANNOUNCEMENT

1/18/2019 jjb

CTD Holdings to Present at Upcoming Brains for Brain Conference on Lysosomal Storage Diseases

CLICK HERE FOR COMPLETE ANNOUNCEMENT

1/10/2019 jjb

CTD Holdings to Present at WORLD Symposium on Lysosomal Storage Diseases

CLICK HERE FOR COMPLETE ANNOUNCEMENT

Phase I Study using Trappsol® Cyclo™ Abstract

Phase I/II Study using Trappsol® Cyclo™ Abstract

12/12/2018 jjb

CTD Announces Partnership with Synteract to support the Extension Protocol for its Phase I Clinical Trial in the United States

CLICK HERE FOR COMPLETE ANNOUNCEMENT

11/8/2018 jjb

CTD Holdings Posts Recording of its Webinar on US Clinical Trial

CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/19/2018 jjb

CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™

CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/16/2018 jjb

CTD Holdings to Host Webinar on its Phase I Clinical Trial for Niemann-Pick disease Type C

CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/11/2018 jjb

CTD Holdings Establishes Second Clinical Trial Site for US Phase I Clinical Study of Trappsol® Cyclo™ for Treatment of NPC

CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/05/2018 jjb

CTD Holdings Announces Top-line Data from Two Ongoing Clinical Trials of Trappsol® Cyclo™ Administered Intravenously in NPC

CLICK HERE FOR COMPLETE ANNOUNCEMENT

10/03/2018 jjb

CTD Holdings Discusses its Phase I Clinical Trial for Intravenous Use of Trappsol® Cyclo™ in Niemann-Pick disease Type C
CLICK HERE FOR COMPLETE ANNOUNCEMENT

08/30/2018 jjb

FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol® Cyclo™ Trial for NPC
CLICK HERE FOR COMPLETE ANNOUNCEMENT

04/30/2018 jjb

CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol® Cyclo™ to Treat Niemann-Pick disease Type C
CLICK HERE FOR COMPLETE ANNOUNCEMENT

03/29/2018 jjb

CTD Holdings’ European Clinical Trial Adopted by National Institute for Health Research of England
CLICK HERE FOR COMPLETE ANNOUNCEMENT

01/17/2018 jjb

CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol(R) Cyclo(TM)
CLICK HERE FOR COMPLETE ANNOUNCEMENT

12/6/2017 cdk

CTD Holdings Enrolls First Patient in
US Phase I Clinical Trial of Trappsol(R) Cyclo(TM)
for Treatment of Niemann-Pick disease Type C

CLICK HERE FOR COMPLETE ANOUNCEMENT

09/28/2017 jjb

CTD Holdings Announces Approval of Clinical Trial
Application to Conduct Phase I/II Clinical Study
of Trappsol(R) Cyclo(TM) in Patients with
Niemann-Pick Type C Disease in Israel

CLICK HERE FOR COMPLETE ANNOUNCEMENT


CTD Holdings Announces First Patient Dosed in
Phase I/II Clinical Trial to Evaluate Trappsol(R)
Cyclo(TM) in Niemann-Pick disease Type C

CLICK HERE FOR COMPLETE ANNOUNCEMENT

07/20/2017 jjb

CTD Holdings Ships Additional
Trappsol® Cyclo™ to Brazil

FULL PRESS RELEASE

06/27/2017 jjb

CTD Holdings Enrolls First Patient in European Phase I/II Clinical Trial of  Trappsol® Cyclo™ for Treatment of Niemann-Pick disease Type C

CLICK HERE FOR COMPLETE ANNOUNCEMENT

06/21/2017 jjb

CTD WEBINAR Clinical Program Update on Trappsol® Cyclo™ Drug Development Program for NPC Treatment

NPC CLINICAL TRIAL WEBINAR

6/13/2017 jjb

CTD Holdings to Host Webinar to Provide Update on Trappsol® Cyclo™ Drug Development Program for NPC Treatment

CLICK HERE FOR MORE INFORMATION

5/16/2017 jjb

CTD Holdings Initiates Recruitment for Phase I/II Clinical Study in Europe of Trappsol® Cyclo™ for Treatment of Niemann-Pick disease Type C

CLICK HERE FOR FULL ANNOUNCEMENT

03/21/2017 jjb

CTD Holdings Closes $2 Million Private Placement

CLICK HERE FOR FULL ANNOUNCEMENT

02/23/2017 jjb

CTD Holdings Presents Compassionate Use Data on Trappsol(R) Cyclo(TM) to Treat Niemann-Pick disease Type C and Provides Update on Progress of U.S. and EU Clinical Trials at 13th Annual WORLDSymposium

CLICK HERE FOR FULL ANNOUNCEMENT

02/20/2017 jjb

FDA Grants Fast Track Designation for Trappsol (R) Cyclo(TM) in Drug Development Program for NPC

CLICK HERE FOR FULL ANNOUNCEMENT

01/17/2017 jjb

CTD Holdings Files Clinical Trial Application with Italian Drug Agency to Continue Advancing Trappsol(R) Cyclo(TM) Drug Development Program to Treat Niemann-Pick disease Type C

CLICK HERE FOR FULL ANNOUNCEMENT

12/22/2016 jjb

CTD HOLDINGS IV TRAPPSOL CYCLO STUDY

The NNPDF Central Office has received notice that CTD’s US trial parameters for the IV Trappsol Cyclo study in NPC are now published at Clinical Trials.Gov.


CTD HOLDINGS PRESS RELEASE

CTD Holdings Announces MHRA Approval of Clinical Trial Application for Treatment of NPC With Trappsol(R) Cyclo(TM)

CLICK HERE FOR FULL RELEASE


09/29/2016 jjb

Supporting one another. Supporting our community